Metin Guclu1, Asuman Ali2, Derya Ustun Eroglu3, Sema Oral Büyükuysal4, Soner Cander1, Nihal Ocak4. 1. 1 Department of Endocrinology and Metabolism, Sevket Yilmaz Research and Training Hospital-Bursa , Bursa, Turkey . 2. 2 Department of Neurology, Sevket Yilmaz Research and Training Hospital-Bursa , Bursa, Turkey . 3. 3 Department of Internal Medicine, Sevket Yilmaz Research and Training Hospital-Bursa , Bursa, Turkey . 4. 4 Department of Biochemistry, Sevket Yilmaz Research and Training Hospital-Bursa , Bursa, Turkey .
Abstract
BACKGROUND: Our aim was to assess serum levels of the soluble receptor for advanced glycation end products (sRAGE) and to examine their association with anthropometric and metabolic parameters in patients with prediabetes and obese controls. METHODS: The two study groups were composed of 42 patients with prediabetes and diabetic neuropathy and 42 age-, gender-, body weight (BW)-, and body mass index (BMI)-matched obese adults as the control group. Prediabetes was diagnosed by the following criteria issued by the American Diabetes Association: impaired fasting glucose [fasting plasma glucose (FPG) level of 100-125 mg/dL], impaired glucose tolerance (2 hr plasma glucose level of 140-199 mg/dL after a 75 grams oral glucose challenge), or a glycated hemoglobin (HbA1C) level of 5.7%-6.4%. RESULTS: There were no differences between the groups in terms of age, gender distribution, BW, or BMI. Despite these similarities, patients with prediabetes had higher FPG, HbA1c, and 2-hr postchallenge glucose levels, higher systolic and diastolic blood pressure, and larger waist and hip circumferences compared with the obese controls. Lipid measurements, complete blood counts, kidney and liver function tests, high-sensitivity C-reactive protein, and sRAGE levels were similar between the two groups. We found significant negative correlations between sRAGE levels and BW, BMI, waist and hip circumferences, waist-to-hip ratios, and low-density lipoprotein (LDL) cholesterol levels. There were no significant correlations with other parameters, including demographic, metabolic, and blood pressure measurements. CONCLUSIONS: In contrast to glycemic parameters, serum levels of sRAGE were negatively correlated with body measurements indicative of obesity in the prediabetic state. In addition, the negative correlation with LDL cholesterol levels suggests that sRAGE has a more robust association with metabolic syndrome than with prediabetes.
BACKGROUND: Our aim was to assess serum levels of the soluble receptor for advanced glycation end products (sRAGE) and to examine their association with anthropometric and metabolic parameters in patients with prediabetes and obese controls. METHODS: The two study groups were composed of 42 patients with prediabetes and diabetic neuropathy and 42 age-, gender-, body weight (BW)-, and body mass index (BMI)-matched obese adults as the control group. Prediabetes was diagnosed by the following criteria issued by the American Diabetes Association: impaired fasting glucose [fasting plasma glucose (FPG) level of 100-125 mg/dL], impaired glucose tolerance (2 hr plasma glucose level of 140-199 mg/dL after a 75 grams oral glucose challenge), or a glycated hemoglobin (HbA1C) level of 5.7%-6.4%. RESULTS: There were no differences between the groups in terms of age, gender distribution, BW, or BMI. Despite these similarities, patients with prediabetes had higher FPG, HbA1c, and 2-hr postchallenge glucose levels, higher systolic and diastolic blood pressure, and larger waist and hip circumferences compared with the obese controls. Lipid measurements, complete blood counts, kidney and liver function tests, high-sensitivity C-reactive protein, and sRAGE levels were similar between the two groups. We found significant negative correlations between sRAGE levels and BW, BMI, waist and hip circumferences, waist-to-hip ratios, and low-density lipoprotein (LDL) cholesterol levels. There were no significant correlations with other parameters, including demographic, metabolic, and blood pressure measurements. CONCLUSIONS: In contrast to glycemic parameters, serum levels of sRAGE were negatively correlated with body measurements indicative of obesity in the prediabetic state. In addition, the negative correlation with LDL cholesterol levels suggests that sRAGE has a more robust association with metabolic syndrome than with prediabetes.
Authors: Stephanie J Loomis; Yuan Chen; David B Sacks; Eric S Christenson; Robert H Christenson; Casey M Rebholz; Elizabeth Selvin Journal: Clin Chem Date: 2017-03-09 Impact factor: 8.327
Authors: Edwin R Miranda; Vikram S Somal; Jacob T Mey; Brian K Blackburn; Edward Wang; Sarah Farabi; Kristian Karstoft; Ciaran E Fealy; Sangeeta Kashyap; John P Kirwan; Laurie Quinn; Thomas P J Solomon; Jacob M Haus Journal: Am J Physiol Endocrinol Metab Date: 2017-08-15 Impact factor: 4.310
Authors: E R Miranda; K N Z Fuller; R K Perkins; C M Kroeger; J F Trepanowski; K A Varady; J M Haus Journal: Nutr Metab Cardiovasc Dis Date: 2018-08-02 Impact factor: 4.222
Authors: Beatriz Paradela-Dobarro; Ángel Fernández-Trasancos; Diana Bou-Teen; Sonia Eiras; Rocío González-Ferreiro; Rosa M Agra; Alfonso Varela-Román; Ana I Castro-Pais; Marcos C Carreira; Felipe F Casanueva; Ezequiel Álvarez; José R González-Juanatey Journal: Cardiovasc Diabetol Date: 2017-09-15 Impact factor: 9.951